By proceeding, you agree to our Terms of Use and Privacy Policy.
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients.
14-14 September 2022
An intensive 1-day meeting that delves into the latest in oligonucleotides chemistry, process & analytical development, therapeutics, antisense therapy & a meeting place for experts working within cutting-edge oligo research & therapeutic development
Event Ended
Virtual
Paid
15-15 September 2022
Our Neuroscience Discovery Symposium will host over 300 key leaders and influencers from global pharmaceutical organisations and leading academic research institutions presenting on the latest developments and critical approaches in neuroscience disc
17-20 October 2022
Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules. We
Hybrid
Boston
16-18 November 2022
THE INDUSTRY’S LEADING EVENT IN EUROPE TO ACCELERATE THERAPEUTICS TO MARKET BY EXPEDITING R&D, IMPROVING CMC EFFICIENCY, AND BUILDING NEW PARTNERSHIPS Access new data & case studies from world-renowned speakers and companies across the entire landsca
Vienna
09-11 January 2023
Biotech Showcase will give you the opportunity to connect with your peers in-person in San Francisco this January. Not ready to travel? Take advantage of our Digital Pass to still be part of the busiest week in healthcare. This event gives you the op
USA
San Francisco
10-10 January 2023
WuXi AppTec is pleased to announce the distinguished speakers and agenda for WuXi Global Forum 2023, which will take place on January 10, 2023 from 1:00 – 6:00 PM PST at Hilton San Francisco Union Square in concurrent with the JP Morgan Healthcare Co
Free
18-19 January 2023
10-13 April 2023
Drug Discovery Chemistry is a dynamic conference for medicinal and biophysical chemists working in pharma, biotech, and academia. Focused on discovery and optimization challenges of small molecule drug candidates, this event provides many exciting op
San Diego
08-09 August 2023
In recent years, Immunotherapy has been at the forefront of oncology research. However, this has not been without issues. Some of which include applications to solid tumors, regulating biodistribution, and serious side effects. During this conference
25-25 September 2023
The coronavirus pandemic ignited interest in learning more about immune responses to infections, their downstream effects, and how they can be modulated. It also gave rise to increased awareness of the role of immunity in diseases like cancer, neurod
Washington, DC
There has been growing interest in targeting kinases such as JAK, TYK, IRAK, SIK, CDK, MEK, ERK, RTK, PLK, PI3K, ALK, MAPK, GSK, LRRK, and more for their role in neurodegeneration, inflammation, cancer, autoimmune, and other disorders. However, targe
26-27 September 2023
Cambridge Healthtech Institute’s two-part conference on Artificial Intelligence (AI)/Machine Learning (ML)-Enabled Drug Discovery will highlight the increasing use of computational tools, AI modeling, algorithms, and data science for identifying nove
While finding novel druggable targets and drug modalities for therapeutic intervention remains a top priority for the pharma/biotech industry, identifying and validating "good" targets and leads remains challenging. Cambridge Healthtech Institute’s c
Cambridge Healthtech Institute's GPCR-Based Drug Discovery conference is now in its 18th year. G protein-coupled receptors (GPCRs), because of their central role in so many cellular processes, are still among the largest class of molecules modulated
Small molecule-based therapeutic options against traditionally hard-to-drug intracellular oncology targets (like KRAS) are being discovered at a more rapid pace and a few have even reached the market in the past few years. Not only do small molecules
As the industry increasingly shifts its attention to biologics, more attention is being paid to the prospect of developing biotherapeutics against membrane-bound targets. For these large target classes, biologics offer improved selectivity, an altern
A new generation of molecules are being developed to disrupt protein-protein interactions and to hijack the cell’s natural machinery for targeted protein degradation. Proteolysis-targeting chimeras (PROTACs), molecular glues, and other modalities are
Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets conference focuses on therapeutic candidates in clinical or earlier stage development that modulate molecules or cellular processes involved in neurodegenerative diseases, especial
27-28 September 2023
Cambridge Healthtech Institute’s annual Lead Generation Strategies conference illuminates the latest approaches used by medicinal, biophysical and computational chemists to discover and develop small molecules (and now slightly larger molecules that
Fibrosis can be viewed as the end-stage of chronic inflammation. Fibrosis and inflammation are related to the immune system gone awry and both underlie many conditions related to aging and therefore are increasing in prevalence in the US. Cambridge H
Transcription factors are proteins with DNA-binding domains that are involved in gene transcription. They are key cell regulators and alterations in their structure, binding, or activity are often found associated with many abnormalities in cellular
02-03 November 2023
This two-day conference will examine the safety, quality, and regulatory issues involved in a wide array of contexts central to the pharmaceutical and biotech industries, including drug packaging and delivery components, single-use systems, medical d
La Jolla